Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding
1. In this pair of identical phase 3 trials involving premenopausal women with uterine fibroids, both elagolix with and without add-back therapy was more...
Cost effectiveness of extending human papillomavirus vaccine administration until age 45
1. The FDA approved the expansion of the human papillomavirus (HPV) vaccination from ages 9 to 26 in women and 21 in men to...
High dose erythropoietin may not be efficacious for neuroprotection in extremely preterm infants
1. In this randomized controlled trial involving extremely preterm infants, high dose erythropoietin did not reduce the risk of death or severe neurodevelopmental impairment...
Niraparib increases progression-free survival in patients with ovarian cancer
1. Niraparib, a PARP (polyadenosine diphosphate ADP-ribose polymerase) inhibitor, has been associated with an increase in progression-free survival among patients with recurrent ovarian cancer.2....
Olaparib plus bevacizumab for ovarian cancer maintenance therapy
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy.2. The progression-free survival benefit...
Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled...
1. Certain dietary supplements, including vitamin B12, iron and omega-3 fatty acids, may negatively impact disease-free survival and overall survival in breast cancer patients...
Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring
1. Children of mothers with diabetes are more likely to develop cardiovascular disease.Evidence Rating Level: 2 (Good)The prevalence of cardiovascular disease (CVD) in children and...
Developmental assessment at 9 months of age can predict fetal alcohol syndrome
1. In this prospective cohort study, infants underwent developmental and dysmorphologic assessments at various times throughout early life. Researchers found that starting at 9...
Association of Widespread Adoption of the 39-Week Rule With Overall Mortality Due to Stillbirth...
1. Following the Joint Commission’s adoption of the 39-week rule to reduce early, elective deliveries, there has been a marginal significant increase in the...
The ORIP trial: n-3 polyunsaturated long chain fatty acid supplementation has no effect on...
1. A multicenter randomized control trial concluded that n-3 polyunsaturated fatty acid supplementation in pregnancy did not change the risk of preterm delivery or...
